ID   NM-D4
AC   CVCL_IQ44
SY   K562-D4
DR   Wikidata; Q54930803
RX   Patent=US8283161;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2605.
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Transformant: ChEBI; CHEBI_23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 17
//
RX   Patent=US8283161;
RA   Goletz, Steffen
RA   Baumeister, Hans
RA   Schlangstedt, Marion
RA   Schober, Ute
RT   "Tumour cell lines and uses thereof.";
RL   Patent number US8283161, 09-Oct-2012.
//